Update on the Treatment of Giant Cell Arteritis and Polymyalgia Rheumatica

Rheum Dis Clin North Am. 2022 May;48(2):493-506. doi: 10.1016/j.rdc.2022.02.007.


Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are considered 2 diseases on the same spectrum due to their many underlying similarities. In recent years, both diseases have witnessed both diagnostic and treatment advances, which shaped the way we manage them. In this article, the authors focus on different diagnostic modalities in GCA as well as the presence of different clinical phenotypes and the role of screening for aortic involvement. The authors also discuss traditional treatments and the role of evolving steroid-sparing agents in the management of both GCA and PMR.

Keywords: Giant cell arteritis; Large vessel vasculitis; Polymyalgia rheumatica; Temporal arteritis; Tocilizumab.

Publication types

  • Review

MeSH terms

  • Giant Cell Arteritis* / diagnosis
  • Giant Cell Arteritis* / drug therapy
  • Glucocorticoids / therapeutic use
  • Humans
  • Polymyalgia Rheumatica* / diagnosis
  • Polymyalgia Rheumatica* / drug therapy


  • Glucocorticoids